Rheumnow Podcast

Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76 Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27)   https://t.co/1REWmod73W Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.

Dr.Jack Cush reviews the hot item takeaways from last weeks RheumNow.Live 2026 Diet & Obesity Management in Rheumatology - Uzma Haque, MD Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD Paradoxical skin reactions – Dr. Joseph Merola Mortality in RA  - Elena Myasoedova, MD The Mucosal Hypothesis to RA - Kristin Demourelle, MD Advances in ILD - Jeffrey Sparks, MD Seronegative vs. Seropositive RA - Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1 🧠 Pathophysiology •Mutant PSTPIP1 - increased interaction with pyrin https://t.co/tJ4INdgfky Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Assoc. w/ Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P  .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096 Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV DMARD Responses in Localized Scleroderma – MMF = MTX ~114 pts Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w

Dr. Jack Cush reviews the news and journal reports from RheumNow.com Top 5 reasons to attend RheumNow Live 2026 1. Its cold and far, but you can be there virtually, online 2. Ffull access to handouts, slides & downloads 3. Saturday concert with Colin Boyd  4. Rohit Agarwal does TWO STEP talks! 5. Download 400+ rheumatology review Questions REGISTER at - RheumNow.live  

Join us for our next webinar: Focus on Guidelines. Panelists will discuss their approaches to a range of difficult cases in multiple areas, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and vasculitis, and discuss how they apply the guidelines in everyday practice. You’ll hear different perspectives and practical tips you can use in clinic. Panelists: Audrey Gibson, PA-C Benjamin A. Smith, PA-C Jack Cush, MD Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot!  This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Dr. Jack Cush reviews rheumatology's highlights, advances and noteworthy trends from the past year - 2025!

1- Sex & the Rheum Patient (12:17) 2- Pain Management (17.58)  3- Lifestyle (15.38)

This podcast is part one of the Mission: APP Partners in Care Therapeutic Update Series called Underserved and under-treated. This podcast includes videos from: Daric Mueller, PA-C, Rachel Busch-Feuer, DNP, Betsy Kirchner, DNP, Lindsay Tom, PA-C and Vanessa Hill, NP-C

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com.  More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Features Dr. Jack Cush

Panelists: Vanessa Hill, NP-C Lindsay Tom, PA-C Barb Slusher Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients?

Join us for our third webinar this month, discussing APP Controversies and Misconceptions. Panelists will cover a range of topics, including APP roles impact; models of care; independence; seeing new patients and complex cases; and more. Panelists: Daric A. Mueller, PA-C Lisa Carnago, MSN, FNP-C, RN Jack Cush, MD